Paula Nigella M, Conzentino Marcelo S, Gonçalves Ana C A, da Silva Renata, Weissheimer Karin V, Kluge Carlos H S, Marins Paulo H S A, Camargo Haxley S C, Farias Lucas R P, Sant'Ana Thamyres P, Vargas Letícia R, Aldrighi Juliane D, Lima Ênio S, Jacotenski Guiomar T, Pedrosa Fabio O, Gonçalves Alan G, Joucoski Emerson, Huergo Luciano F
Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil.
Graduated Program in Sciences-Biochemistry, UFPR, Curitiba 81531-980, PR, Brazil.
Vaccines (Basel). 2022 Dec 22;11(1):21. doi: 10.3390/vaccines11010021.
(1) Background: COVID-19 vaccination in Brazil has been performed mostly with CoronaVac (Sinovac), ChAdOx1-S (AstraZeneca-University of Oxford) and BNT162b2 (Pfizer-BioNTech) vaccines. The titers of IgG antibodies reactive to the SARS-CoV-2 spike protein correlate with vaccine efficacy. Studies comparing vaccine immunogenicity in a real-world scenario are lacking. (2) Methods: We performed a population-based study to analyze the immunoglobulin G response to different COVID-19 vaccines. Citizens older than 18 years (n = 2376) provided personal data, a self-declaration of any previous COVID-19 positive tests and information regarding COVID-19 vaccination: the vaccine popular name and the date of each dose. Blood samples were collected and the levels of IgG reactive to SARS-CoV-2 antigens were determined and compared between different vaccine groups. (3) Results: The seroconversion for anti-spike IgG achieved > 95% by February 2022 and maintained stable until June 2022. Higher anti-spike IgG titers were detected in individuals vaccinated with BNT162b2, followed by ChAdOx1-S and CoronaVac. The anti-spike IgG response was negatively correlated with age and interval after the second dose for the BNT162b2 vaccine. Natural infections boosted anti-spike IgG in those individuals who completed primary vaccination with ChAdOx1-S and CoronaVac, but not with BNT162b2. The levels of anti-spike IgG increased with the number of vaccine doses administered. The application of BNT162b2 as a 3rd booster dose resulted in high anti-spike IgG antibody titers, despite the type of vaccine used during primary vaccination. (4) Conclusions: Our data confirmed the effectiveness of the Brazilian vaccination program. Of the vaccines used in Brazil, BNT162b2 performed better to elicit anti-spike protein IgG after primary vaccination and as a booster dose and thus should be recommended as a booster whenever available. A continuous COVID-19 vaccination program will be required to sustain anti-spike IgG antibodies in the population.
(1) 背景：巴西的新冠疫苗接种主要使用了科兴新冠疫苗（Sinovac）、牛津大学/阿斯利康ChAdOx1-S疫苗以及辉瑞/BioNTech的BNT162b2疫苗。对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白产生反应的IgG抗体滴度与疫苗效力相关。目前缺乏在真实世界场景中比较疫苗免疫原性的研究。(2) 方法：我们开展了一项基于人群的研究，以分析对不同新冠疫苗的免疫球蛋白G反应。18岁以上的公民（n = 2376）提供了个人数据、既往任何新冠病毒检测呈阳性的自我声明以及有关新冠疫苗接种的信息：疫苗通用名称和每剂接种日期。采集血样，测定对SARS-CoV-2抗原产生反应的IgG水平，并在不同疫苗组之间进行比较。(3) 结果：截至2022年2月，抗刺突IgG的血清转化率达到>95%，并一直稳定至2022年6月。接种BNT162b2疫苗的个体中检测到更高的抗刺突IgG滴度，其次是ChAdOx1-S疫苗和科兴新冠疫苗。对于BNT162b2疫苗，抗刺突IgG反应与年龄以及第二剂接种后的时间间隔呈负相关。自然感染增强了那些完成ChAdOx1-S疫苗和科兴新冠疫苗基础免疫的个体的抗刺突IgG，但对完成BNT162b2疫苗基础免疫的个体则没有增强作用。抗刺突IgG水平随着接种疫苗剂量的增加而升高。无论基础免疫使用何种疫苗，应用BNT162b2作为第三剂加强针均能产生高抗刺突IgG抗体滴度。(4) 结论：我们的数据证实了巴西疫苗接种计划的有效性。在巴西使用的疫苗中，BNT162b2在基础免疫和作为加强针接种后诱导产生抗刺突蛋白IgG方面表现更佳，因此只要有条件，应推荐其作为加强针。需要持续的新冠疫苗接种计划来维持人群中的抗刺突IgG抗体水平。
